Intrinsic value of Egalet - EGLT

Previous Close

$0.72

  Intrinsic Value

$0.03

stock screener

  Rating & Target

str. sell

-96%

Previous close

$0.72

 
Intrinsic value

$0.03

 
Up/down potential

-96%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of EGLT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of Egalet (EGLT) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -26.09
  40.00
  36.50
  33.35
  30.52
  27.96
  25.67
  23.60
  21.74
  20.07
  18.56
  17.20
  15.98
  14.89
  13.90
  13.01
  12.21
  11.49
  10.84
  10.25
  9.73
  9.26
  8.83
  8.45
  8.10
  7.79
  7.51
  7.26
  7.04
  6.83
  6.65
Revenue, $m
  17
  24
  32
  43
  57
  72
  91
  112
  137
  164
  195
  228
  265
  304
  346
  391
  439
  490
  543
  598
  657
  717
  781
  847
  915
  987
  1,061
  1,138
  1,218
  1,301
  1,388
Variable operating expenses, $m
 
  77
  105
  140
  183
  234
  294
  364
  443
  531
  630
  738
  856
  984
  1,121
  1,266
  1,421
  1,584
  1,756
  1,936
  2,124
  2,321
  2,526
  2,739
  2,961
  3,192
  3,432
  3,681
  3,940
  4,209
  4,489
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  98
  77
  105
  140
  183
  234
  294
  364
  443
  531
  630
  738
  856
  984
  1,121
  1,266
  1,421
  1,584
  1,756
  1,936
  2,124
  2,321
  2,526
  2,739
  2,961
  3,192
  3,432
  3,681
  3,940
  4,209
  4,489
Operating income, $m
  -81
  -53
  -73
  -97
  -126
  -162
  -203
  -251
  -306
  -367
  -435
  -510
  -592
  -680
  -774
  -875
  -982
  -1,094
  -1,213
  -1,337
  -1,468
  -1,603
  -1,745
  -1,892
  -2,046
  -2,205
  -2,371
  -2,543
  -2,722
  -2,908
  -3,101
EBITDA, $m
  -77
  -48
  -65
  -87
  -113
  -145
  -182
  -225
  -274
  -329
  -391
  -458
  -531
  -610
  -695
  -785
  -881
  -982
  -1,089
  -1,200
  -1,317
  -1,439
  -1,566
  -1,698
  -1,836
  -1,979
  -2,127
  -2,282
  -2,442
  -2,609
  -2,783
Interest expense (income), $m
  0
  3
  0
  1
  1
  2
  3
  4
  5
  6
  8
  9
  11
  13
  15
  17
  19
  22
  25
  27
  30
  33
  36
  40
  43
  47
  50
  54
  58
  62
  67
Earnings before tax, $m
  -92
  -56
  -73
  -98
  -128
  -164
  -206
  -255
  -311
  -373
  -443
  -519
  -603
  -693
  -789
  -892
  -1,001
  -1,116
  -1,238
  -1,365
  -1,498
  -1,637
  -1,781
  -1,932
  -2,089
  -2,252
  -2,421
  -2,597
  -2,780
  -2,970
  -3,168
Tax expense, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -91
  -56
  -73
  -98
  -128
  -164
  -206
  -255
  -311
  -373
  -443
  -519
  -603
  -693
  -789
  -892
  -1,001
  -1,116
  -1,238
  -1,365
  -1,498
  -1,637
  -1,781
  -1,932
  -2,089
  -2,252
  -2,421
  -2,597
  -2,780
  -2,970
  -3,168

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  87
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  115
  39
  54
  71
  93
  119
  150
  185
  225
  271
  321
  376
  436
  501
  571
  645
  724
  807
  894
  986
  1,082
  1,182
  1,286
  1,395
  1,508
  1,625
  1,748
  1,874
  2,006
  2,143
  2,286
Adjusted assets (=assets-cash), $m
  28
  39
  54
  71
  93
  119
  150
  185
  225
  271
  321
  376
  436
  501
  571
  645
  724
  807
  894
  986
  1,082
  1,182
  1,286
  1,395
  1,508
  1,625
  1,748
  1,874
  2,006
  2,143
  2,286
Revenue / Adjusted assets
  0.607
  0.615
  0.593
  0.606
  0.613
  0.605
  0.607
  0.605
  0.609
  0.605
  0.607
  0.606
  0.608
  0.607
  0.606
  0.606
  0.606
  0.607
  0.607
  0.606
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
Average production assets, $m
  20
  27
  37
  50
  65
  83
  104
  129
  157
  188
  223
  262
  304
  349
  397
  449
  504
  562
  623
  686
  753
  823
  896
  971
  1,050
  1,132
  1,217
  1,305
  1,397
  1,492
  1,591
Working capital, $m
  68
  -27
  -36
  -48
  -63
  -81
  -102
  -126
  -153
  -184
  -218
  -255
  -296
  -340
  -387
  -438
  -491
  -547
  -607
  -669
  -734
  -802
  -873
  -947
  -1,023
  -1,103
  -1,186
  -1,272
  -1,362
  -1,455
  -1,551
Total debt, $m
  84
  9
  22
  38
  58
  81
  109
  141
  177
  218
  263
  312
  367
  425
  488
  554
  625
  700
  779
  861
  948
  1,038
  1,132
  1,229
  1,331
  1,437
  1,547
  1,661
  1,780
  1,903
  2,031
Total liabilities, $m
  110
  35
  48
  64
  84
  107
  135
  167
  203
  244
  289
  338
  393
  451
  514
  580
  651
  726
  805
  887
  974
  1,064
  1,158
  1,255
  1,357
  1,463
  1,573
  1,687
  1,806
  1,929
  2,057
Total equity, $m
  5
  4
  5
  7
  9
  12
  15
  19
  23
  27
  32
  38
  44
  50
  57
  64
  72
  81
  89
  99
  108
  118
  129
  139
  151
  163
  175
  187
  201
  214
  229
Total liabilities and equity, $m
  115
  39
  53
  71
  93
  119
  150
  186
  226
  271
  321
  376
  437
  501
  571
  644
  723
  807
  894
  986
  1,082
  1,182
  1,287
  1,394
  1,508
  1,626
  1,748
  1,874
  2,007
  2,143
  2,286
Debt-to-equity ratio
  16.800
  2.370
  4.140
  5.360
  6.210
  6.820
  7.260
  7.600
  7.850
  8.040
  8.190
  8.310
  8.400
  8.480
  8.540
  8.600
  8.640
  8.680
  8.710
  8.740
  8.760
  8.780
  8.800
  8.810
  8.830
  8.840
  8.850
  8.860
  8.870
  8.880
  8.890
Adjusted equity ratio
  -2.929
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -91
  -56
  -73
  -98
  -128
  -164
  -206
  -255
  -311
  -373
  -443
  -519
  -603
  -693
  -789
  -892
  -1,001
  -1,116
  -1,238
  -1,365
  -1,498
  -1,637
  -1,781
  -1,932
  -2,089
  -2,252
  -2,421
  -2,597
  -2,780
  -2,970
  -3,168
Depreciation, amort., depletion, $m
  4
  5
  7
  10
  13
  17
  21
  26
  31
  38
  45
  52
  61
  70
  79
  90
  101
  112
  125
  137
  151
  165
  179
  194
  210
  226
  243
  261
  279
  298
  318
Funds from operations, $m
  -71
  -51
  -65
  -88
  -115
  -147
  -185
  -229
  -279
  -336
  -398
  -467
  -542
  -623
  -710
  -802
  -900
  -1,004
  -1,113
  -1,227
  -1,347
  -1,472
  -1,602
  -1,738
  -1,879
  -2,025
  -2,178
  -2,336
  -2,501
  -2,672
  -2,849
Change in working capital, $m
  2
  -8
  -10
  -12
  -15
  -18
  -21
  -24
  -27
  -31
  -34
  -37
  -41
  -44
  -47
  -50
  -53
  -56
  -59
  -62
  -65
  -68
  -71
  -74
  -77
  -80
  -83
  -86
  -89
  -93
  -97
Cash from operations, $m
  -73
  -43
  -56
  -76
  -100
  -129
  -164
  -205
  -252
  -305
  -364
  -430
  -501
  -579
  -662
  -752
  -847
  -948
  -1,054
  -1,165
  -1,282
  -1,404
  -1,531
  -1,664
  -1,802
  -1,946
  -2,095
  -2,250
  -2,411
  -2,579
  -2,753
Maintenance CAPEX, $m
  0
  -4
  -5
  -7
  -10
  -13
  -17
  -21
  -26
  -31
  -38
  -45
  -52
  -61
  -70
  -79
  -90
  -101
  -112
  -125
  -137
  -151
  -165
  -179
  -194
  -210
  -226
  -243
  -261
  -279
  -298
New CAPEX, $m
  -7
  -8
  -10
  -12
  -15
  -18
  -21
  -25
  -28
  -31
  -35
  -38
  -42
  -45
  -48
  -52
  -55
  -58
  -61
  -64
  -67
  -70
  -73
  -76
  -79
  -82
  -85
  -88
  -92
  -95
  -99
Cash from investing activities, $m
  49
  -12
  -15
  -19
  -25
  -31
  -38
  -46
  -54
  -62
  -73
  -83
  -94
  -106
  -118
  -131
  -145
  -159
  -173
  -189
  -204
  -221
  -238
  -255
  -273
  -292
  -311
  -331
  -353
  -374
  -397
Free cash flow, $m
  -24
  -55
  -71
  -95
  -125
  -161
  -202
  -251
  -306
  -368
  -437
  -513
  -595
  -685
  -781
  -883
  -992
  -1,106
  -1,227
  -1,354
  -1,486
  -1,624
  -1,769
  -1,919
  -2,075
  -2,237
  -2,406
  -2,582
  -2,764
  -2,953
  -3,150
Issuance/(repayment) of debt, $m
  21
  -75
  13
  16
  20
  23
  28
  32
  36
  41
  45
  50
  54
  58
  63
  67
  71
  75
  79
  83
  86
  90
  94
  98
  102
  106
  110
  114
  119
  123
  128
Issuance/(repurchase) of shares, $m
  0
  142
  74
  99
  130
  166
  209
  259
  315
  378
  448
  525
  609
  699
  796
  899
  1,009
  1,125
  1,246
  1,374
  1,507
  1,647
  1,792
  1,943
  2,100
  2,263
  2,433
  2,610
  2,793
  2,984
  3,182
Cash from financing (excl. dividends), $m  
  22
  67
  87
  115
  150
  189
  237
  291
  351
  419
  493
  575
  663
  757
  859
  966
  1,080
  1,200
  1,325
  1,457
  1,593
  1,737
  1,886
  2,041
  2,202
  2,369
  2,543
  2,724
  2,912
  3,107
  3,310
Total cash flow (excl. dividends), $m
  -2
  13
  16
  20
  24
  29
  34
  40
  45
  51
  56
  62
  67
  73
  78
  83
  88
  93
  98
  103
  108
  112
  117
  122
  127
  132
  137
  142
  148
  154
  160
Retained Cash Flow (-), $m
  84
  -142
  -74
  -99
  -130
  -166
  -209
  -259
  -315
  -378
  -448
  -525
  -609
  -699
  -796
  -899
  -1,009
  -1,125
  -1,246
  -1,374
  -1,507
  -1,647
  -1,792
  -1,943
  -2,100
  -2,263
  -2,433
  -2,610
  -2,793
  -2,984
  -3,182
Prev. year cash balance distribution, $m
 
  87
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -42
  -58
  -79
  -105
  -137
  -175
  -219
  -270
  -327
  -392
  -463
  -541
  -626
  -718
  -816
  -921
  -1,031
  -1,148
  -1,271
  -1,400
  -1,534
  -1,675
  -1,821
  -1,973
  -2,132
  -2,296
  -2,467
  -2,645
  -2,830
  -3,022
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  -41
  -53
  -69
  -87
  -106
  -127
  -148
  -168
  -188
  -205
  -220
  -231
  -238
  -241
  -240
  -234
  -224
  -211
  -196
  -178
  -159
  -139
  -119
  -101
  -83
  -67
  -53
  -41
  -31
  -23
Current shareholders' claim on cash, %
  100
  50.0
  12.4
  3.1
  0.8
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

FINANCIAL RATIOS  of  Egalet (EGLT)

Valuation Ratios
P/E Ratio -0.2
Price to Sales 1.1
Price to Book 3.6
Price to Tangible Book
Price to Cash Flow -0.2
Price to Free Cash Flow -0.2
Growth Rates
Sales Growth Rate -26.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 75%
Cap. Spend. - 3 Yr. Gr. Rate 28.5%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1680%
Total Debt to Equity 1680%
Interest Coverage 0
Management Effectiveness
Return On Assets -63.4%
Ret/ On Assets - 3 Yr. Avg. -73.1%
Return On Total Capital -77.8%
Ret/ On T. Cap. - 3 Yr. Avg. -102.6%
Return On Equity -193.6%
Return On Equity - 3 Yr. Avg. -177.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 76.5%
Gross Margin - 3 Yr. Avg. 54.5%
EBITDA Margin -517.6%
EBITDA Margin - 3 Yr. Avg. -953.7%
Operating Margin -476.5%
Oper. Margin - 3 Yr. Avg. -850.9%
Pre-Tax Margin -541.2%
Pre-Tax Margin - 3 Yr. Avg. -982.6%
Net Profit Margin -535.3%
Net Profit Margin - 3 Yr. Avg. -979.2%
Effective Tax Rate 1.1%
Eff/ Tax Rate - 3 Yr. Avg. 0.9%
Payout Ratio 0%

EGLT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EGLT stock intrinsic value calculation we used $17 million for the last fiscal year's total revenue generated by Egalet. The default revenue input number comes from 2016 income statement of Egalet. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EGLT stock valuation model: a) initial revenue growth rate of 40% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EGLT is calculated based on our internal credit rating of Egalet, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Egalet.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EGLT stock the variable cost ratio is equal to 323.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for EGLT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Egalet.

Corporate tax rate of 27% is the nominal tax rate for Egalet. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EGLT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EGLT are equal to 114.7%.

Life of production assets of 4.9 years is the average useful life of capital assets used in Egalet operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EGLT is equal to -111.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $5 million for Egalet - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.46 million for Egalet is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Egalet at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
NKTR Nektar Therape 89.60 0.26  str.sell
DEPO DepoMed 7.55 0.97  str.sell
DRRX Durect 1.13 0.00  str.sell
TEVA Teva Pharmaceu 20.04 42.97  str.buy

COMPANY NEWS

▶ Egalet to Co-Host Category 1 Focus Group   [Jan-24-18 06:02AM  PR Newswire]
▶ Egalet targeting dentists in co-promotion deal with Montco firm   [Jan-03-18 01:15PM  American City Business Journals]
▶ ETFs with exposure to Egalet Corp. : December 26, 2017   [Dec-26-17 11:27AM  Capital Cube]
▶ EGLT: Debt Refinancing With Benefits   [Dec-22-17 10:00AM  Zacks Small Cap Research]
▶ ETFs with exposure to Egalet Corp. : December 5, 2017   [Dec-05-17 12:43PM  Capital Cube]
▶ EGLT: Impressive Prescription Growth; Revenues Should Follow   [Nov-22-17 03:00PM  Zacks Small Cap Research]
▶ ETFs with exposure to Egalet Corp. : November 20, 2017   [Nov-20-17 12:19PM  Capital Cube]
▶ ETFs with exposure to Egalet Corp. : November 9, 2017   [Nov-09-17 12:38PM  Capital Cube]
▶ Egalet Corporation to Host Earnings Call   [Nov-08-17 06:40AM  ACCESSWIRE]
▶ Egalet reports 3Q loss   [06:09AM  Associated Press]
▶ ETFs with exposure to Egalet Corp. : October 30, 2017   [Oct-30-17 11:43AM  Capital Cube]
▶ Egalet (EGLT): The Guardian of Misuse and Abuse   [Oct-24-17 09:00AM  Zacks Small Cap Research]
▶ ETFs with exposure to Egalet Corp. : October 20, 2017   [Oct-20-17 10:11AM  Capital Cube]
▶ ETFs with exposure to Egalet Corp. : October 9, 2017   [Oct-09-17 11:28AM  Capital Cube]
▶ Egalet to Present at Investor Conferences this Fall   [Sep-06-17 06:02AM  PR Newswire]
▶ Egalet reports 2Q loss   [Aug-09-17 10:03PM  Associated Press]
▶ Egalet trims non-sales workforce by 40%   [05:20PM  American City Business Journals]
▶ Egalet Stumbles Over FDA Complete Response Letter   [Jun-20-17 10:15AM  24/7 Wall St.]
▶ ETFs with exposure to Egalet Corp. : June 8, 2017   [Jun-08-17 01:33PM  Capital Cube]
▶ Patents piling up for Wayne maker of abuse-deterrent medicines   [Jun-05-17 02:40PM  American City Business Journals]
▶ ETFs with exposure to Egalet Corp. : May 26, 2017   [May-26-17 01:06PM  Capital Cube]
▶ ETFs with exposure to Egalet Corp. : May 15, 2017   [May-15-17 03:38PM  Capital Cube]
▶ Egalet reports 1Q loss   [May-10-17 06:22AM  Associated Press]
▶ Egalet to Participate in Spring Investor Conferences   [Apr-03-17 06:02AM  PR Newswire]
▶ Egalet Gets 4 New Patents for Guardian Technology   [Mar-23-17 11:05AM  at Investopedia]
▶ Nektar Pharma Opioid Drug Shows Promise In Phase 3   [Mar-20-17 01:41PM  at Investopedia]
Financial statements of EGLT
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.